Response by Gheblawi et al to Letter Regarding Article, “Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2”

Author:

Gheblawi Mahmoud12,Wang Kaiming32,Viveiros Anissa12,Nguyen Quynh32,Zhong Jiu-Chang4,Turner Anthony J.5,Raizada Mohan K.6,Grant Maria B.7,Oudit Gavin Y.132ORCID

Affiliation:

1. From the Department of Physiology (M.G., A.V., G.Y.O.), University of Alberta, Edmonton, Canada

2. Mazankowski Alberta Heart Institute (M.G., K.W., A.V., Q.N., G.Y.O.), University of Alberta, Edmonton, Canada

3. Division of Cardiology, Department of Medicine (K.W., Q.N., G.Y.O.), University of Alberta, Edmonton, Canada

4. Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, China (J.Z.)

5. School of Biomedical Sciences, University of Leeds, United Kingdom (A.J.T.)

6. Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville (M.K.R.)

7. Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham (M.B.G.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference9 articles.

1. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

2. Angiotensin Converting Enzyme 2

3. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19 [published online May 1, 2020].;Reynolds HR;N Engl J Med

4. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

5. Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (covid-19).;Mehta N;JAMA Cardiol,2020

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3